ELEV — Elevation Oncology Income Statement
0.000.00%
Last trade - 00:00- $20.31m
- -$41.74m
Annual income statement for Elevation Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.3 | 32 | 94.5 | 45.4 | 45.6 |
| Operating Profit | -17.3 | -32 | -94.5 | -45.4 | -45.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.3 | -32 | -95.1 | -45.7 | -44.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.3 | -32 | -95.1 | -45.7 | -44.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.3 | -32 | -95.1 | -45.7 | -44.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.3 | -32 | -95.1 | -45.7 | -44.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.758 | -2.64 | -4.09 | -1.24 | -0.766 |
| Dividends per Share |